



Cite this: DOI: 10.1039/c5an01864a

Surface plasmon resonance biosensors for simultaneous monitoring of amyloid-beta oligomers and fibrils and screening of select modulators

Xinyao Yi,^{a,b} Chengting Feng,^a Shengqiang Hu,^a Hengfeng Li^b and Jianxiu Wang^{*a}

Oligomeric amyloid-beta (A β) peptides are considered as the most toxic species in Alzheimer's disease (AD). Monitoring of the A β aggregation profiles is critical for elucidating the oligomer toxicity and may serve as a therapeutic target for AD. By immobilizing the capture antibodies of A11 and OC that are specific to the oligomers and fibrils, respectively, in separate fluidic channels, a novel surface plasmon resonance (SPR) biosensor was designed for monitoring the oligomeric and fibrillar species of A β (1–42) simultaneously. The influence of curcumin, Cu²⁺ and methylene blue on the amount of toxic oligomers and fibrils was evaluated. The half maximal inhibitory concentration (IC₅₀) of curcumin and methylene blue was determined. The formation of A β fibrils was also validated by the thioflavin T (ThT) fluorescence assay. The results demonstrate the utility of SPR as an analytical tool for rapid and comprehensive monitoring of A β aggregation and screening of A β modulators.

Received 10th September 2015,
Accepted 17th November 2015

DOI: 10.1039/c5an01864a

www.rsc.org/analyst

Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder and one of its hallmarks is the deposition of neuritic senile plaques in the brains of AD patients. The major constituent of the neuritic plaques is an amyloid- β (A β) peptide with 39–43 amino acids cleaved from an amyloid precursor protein by β - and γ -secretases.^{1,2} Typically, the cerebral deposition of A β has been indicated as a key process associated with the progression of AD.^{3,4} The aggregation of A β is a complicated process involving the conversion of soluble monomers to oligomers and fibrils.³ Oligomers were thought to be the most toxic species which disrupt synaptic plasticity and cause neuronal injury.^{5–7} One way to lower the toxicity is to prevent the production of A β by inhibiting the enzymatic activity of β - and γ -secretases.^{8–10} The use of modulators to inhibit the oligomer formation is another way to reduce the toxicity.⁴ Thus, the study of A β aggregation is related to AD therapy and represents a significant area of AD-related research.

To delineate the mechanism of AD progression and to screen select aggregation modulators, monitoring of A β aggregation profiles is of great importance. Although a variety of structure- or morphology-based techniques, such as solid-state

NMR,¹¹ atomic force microscopy (AFM)¹² and X-ray diffraction¹³ have provided insights into the molecular basis of amyloid aggregation, optical dye-binding techniques are the most frequently used ones to monitor the kinetics of the aggregation process in real time and to screen small-molecule aggregation inhibitors.¹⁴ In such an assay, the absorption and/or fluorescence properties of congo red and thioflavin T (ThT) were examined when bound to the aggregates of the amyloidogenic peptides. However, the binding of dyes prevented natural oligomer formation, and the assay is prone to false positive results.^{15–17} Enzyme-linked immunosorbent assay is another frequently used technique for the detection of A β monomers or oligomers. However, it usually suffers from cross-reactivity, nonspecific binding, and low stability of the enzyme conjugates.^{18,19} Fluorescence resonance energy transfer using a combination of extrinsic fluorophores has also been demonstrated for the detection of amyloid aggregation.^{20–22} For example, *in situ* and simultaneous monitoring of the oligomers and fibrils of amyloidogenic peptides was conducted.²⁰ As donors and acceptors, the fluorophores were covalently attached to or mechanically mixed with the amyloidogenic peptides.^{20–22} However, the feasibility of the assays depends on the distance between the binding sites and the covalent modification of the peptides with the fluorophores making these assays complicated and time-consuming.

Surface plasmon resonance (SPR) serves as a viable alternative for studying the biomolecular interactions and their kinetics.^{23,24} In contrast to other techniques, SPR is capable of

^aCollege of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan, P. R. China 410083. E-mail: jxiu.wang@csu.edu.cn

^bSchool of Materials Science and Engineering, Central South University, Changsha, Hunan, P. R. China 410083

determining the target biomolecules in a real-time and label-free manner.^{25–27} The aggregation of the A β (1–42) peptide from fresh monomers to fully-grown fibrils was analyzed by SPR and AFM.²⁸ The presence of Fe³⁺ was demonstrated to induce significantly denser aggregates. Compared to the dye-binding assays, SPR does not involve additives or a further labeling step, and a direct assay of the fibrillation of A β (1–42) from the initial monomeric species was performed.²⁸ However, the specific forms of A β oligomers and fibrils during the aggregation process were not determined by this method. Monitoring of A β fibril elongation under different immobilized “seed” conditions was demonstrated by surface plasmon resonance imaging.²⁹ The effect of epigallocatechin-3-gallate and various metal ions (Fe³⁺, Cu²⁺, and Zn²⁺) on the growth of A β fibrils was examined. Although multiple assays were achieved, the use of a CCD camera compromises the detection sensitivity.^{26,30}

Veloso *et al.* studied the aggregation of A β by electrochemical impedance spectroscopy using the antibodies of A11 and OC that are specific to the oligomers and fibrils, respectively.³¹ The surface binding reaction was measured by determining the charge transfer resistance of the [Fe(CN)₆]^{3–/4–} redox probe. The *sym*-triazine-derived aggregation modulators to reduce the amount of toxic oligomers were examined. However, in that work, the sensing protocol is complicated and the results are uncomparable because the A11 and OC antibodies were modified onto different electrodes and the antigen–antibody interaction was not measured simultaneously.

In this study, a SPR biosensor for analyzing A β aggregation was designed. Oligomeric and fibrillar species of A β (1–42) were captured by their respective antibodies immobilized onto different fluidic channels of one chip and the aggregation profiles were attained. The effect of several modulators on the distribution of the oligomeric and fibrillar species was also examined. The sensing protocol enables the monitoring of the A β aggregation process on two channels of one single chip, and consequently the assay accuracy and reproducibility were significantly improved.

Experimental section

Chemicals and materials

16-Mercaptohexadecan-1-ol was purchased from Frontier Scientific, Inc. (Logan, Utah). Diethylene glycol dimethyl ether, epichlorohydrin, dextran, bromoacetic acid, *N*-hydroxysuccinimide (NHS), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (EDC), ethanolamine hydrochloride (EA), NaH₂PO₄, and Na₂HPO₄ were acquired from Sigma (St. Louis, MO). A11 antibody that is specific to the oligomers and OC antibody which recognizes the fibrils were obtained from Millipore Inc. (Dedham, MA). A β (1–42) was purchased from American Peptide Inc. (Sunnyvale, CA). Curcumin, methylene blue, and CuCl₂ were obtained from Sinopharm Chemical Reagent Co., Ltd (China). Other reagents were of analytical purity and

used as received. All stock solutions were prepared daily with deionized water treated with a water purification system (Simplicity 185, Millipore Corp., Billerica, MA). The stock solutions of A β (1–42) (0.2 mM) and the antibodies were diluted with the phosphate buffer (10 mM phosphate, pH 7.4). The diluted A β (1–42) solution was then incubated alone and with curcumin or Cu²⁺ or methylene blue for different time periods.

Instruments

The SPR measurements were conducted on a BI-SPR 3000 system (Biosensing Instrument Inc., Tempe, AZ). The phosphate buffer was degassed under vacuum for 30 min and used as the carrier solution. The fluorescence emission spectra were obtained on a Hitachi F-4600 spectrofluorometer (Hitachi, Japan).

Procedures

Au films coated onto BK7 glass slides were purchased from Biosensing Instrument Inc. (Tempe, AZ) and annealed in a hydrogen flame to eliminate surface contaminants. The carboxymethylated dextran (CM-dextran)-covered SPR chips were prepared according to the literature reported.³² *Via* the amide bond formation, channel 1 and channel 2 were coated with A11 and OC antibodies, respectively. Both the channels were treated with 1 M EA to block the empty sites. The incubated samples of A β (1–42) in the absence and presence of curcumin or Cu²⁺ or methylene blue were preloaded into a 200 μ L sample loop on an injection valve and then delivered to the flow cell by a syringe pump (Model KDS260, KD Scientific, Holliston, MA). The flow rate was maintained at 20 μ L min^{–1}.

Results and discussion

The schematic diagram of the simultaneous SPR determination of A β (1–42) oligomers and fibrils is illustrated in Fig. 1. Modifying the Au chips with CM-dextran molecules reduces the nonspecific adsorption of the various forms of A β . The A11 and OC antibodies were individually immobilized onto the CM-dextran-covered chips *via* amine coupling. The A11 anti-




Fig. 1 Schematic representation of simultaneous SPR detection of A β (1–42) oligomers and fibrils. Carboxymethylated (CM)-dextran-covered SPR chips were modified with the A11 antibody (channel 1, CH1) and OC antibody (channel 2, CH2), which are specific to the oligomers and fibrils, respectively. Injection of the pre-incubated A β (1–42) sample results in the attachment of the oligomers and fibrils onto the respective antibody-coated surfaces. For clarity, the molecules are not drawn to scale.

body recognizes the epitopes of the toxic oligomeric intermediates of the amyloidogenic proteins, and does not recognize the monomers, dimers, trimers, tetramers and fibrils.³³ Meanwhile the OC antibody reacts specifically with the fibrils.³⁴ When the various A β aggregates or the mixture of A β aggregates with select modulators were flowed over the sensor surface, the oligomers and fibrils were captured by their corresponding antibodies which were immobilized onto separate fluidic channels. The molecular weight of the oligomers or fibrils is high enough to produce a reasonable SPR signal. The sensor chip can be regenerated with NaOH for multiple and continuous SPR assays on one chip. Thus, SPR provides a rapid and comprehensive means to monitor the various forms of A β , to evaluate the pathways of A β assembly and to screen the candidate compounds that modulate the aggregation process of A β .

The aggregation of A β (1–42) was stimulated by incubation under physiological conditions at various time points. At each measured time point, the samples were serially flowed over the two channels to measure the distribution of the oligomers and fibrils. Time-dependent SPR sensorgrams upon injection of the incubated samples were acquired at the sensor chips pre-immobilized with A11 antibody (Fig. 2A) and OC antibody (Fig. 2B). The difference in the baseline SPR angles before and after the injection reflects the amount of the bound species. The nonspecific adsorption (2–3 mdeg) was subtracted *via* the injection of the incubated samples onto the CM-dextran-covered SPR chip. At the time point of 0 h, no SPR signals in curves a of Fig. 2A and B were expected because the incubated samples are monomer-dominated, and the monomers cannot be recognized by the A11 or OC antibody. With the increase of the incubation time, a gradual increase in the SPR signals in Fig. 2B was obtained, indicating an increased tendency of fibril formation. The highest SPR signal was obtained at 24 h, and beyond 24 h, the SPR signals remain unchanged, indicating a saturated aggregation process. Such a trend is in accordance with the predicted nucleation-dependent process of A β aggregation.³⁵ As for CH1, the SPR signals at the A11 antibody-covered surface increased with the incubation time less than 6 h (curves a–e, Fig. 2A), suggesting that the oligomers were

gradually formed with time. However, when the incubation time exceeds 6 h, the SPR signals decreased (curves f and g, Fig. 2A). This was caused by further aggregation of the oligomers to amorphous forms, protofibrils or fibrils, which cannot be recognized by the A11 antibody. Monitoring of A β aggregation profiles on one single chip leads to excellent reproducibility and accuracy of the assay. SPR thus provides a viable alternative for monitoring of the aggregation process of A β (1–42).

Time-dependent distribution of the oligomers in the absence (A) and presence of curcumin (B), Cu²⁺ (C) and methylene blue (D) is shown in Fig. 3. Curcumin, Cu²⁺ and methylene blue were chosen as modulators of A β aggregation in this study. The amount of the oligomers increased with the incubation time and reached the maximum value at 6 h (Fig. 3A). Beyond 6 h, the oligomers were gradually aggregated to fibrils, as evidenced by the decreased SPR signals at the A11 antibody-covered surface (CH1) (Fig. 2A and 3A). Curcumin was used as a classic modulator which suppresses the morbidity of AD.^{36,37} The treatment of A β (1–42) with curcumin results in a much smaller SPR signal (Fig. 3B), indicating that curcumin is a potential inhibitor of A β (1–42) oligomer formation. Cu²⁺ is capable of binding with A β , which accelerates the aggregation process of A β .^{38,39} As shown in Fig. 3C, Cu²⁺-treated A β (1–42) appeared to promote the oligomer formation, because the maximum SPR signal was achieved after 4 h incubation. The above results are in agreement with the previous reports that curcumin suppressed the oligomer formation and Cu²⁺ improved the oligomerization of A β .^{29,36,40} As a leading compound in drug research, methylene blue has attracted much attention for its ability to modulate amyloid fibrilla-




Fig. 2 SPR sensorgrams showing the capture of (A) oligomers of A β (1–42) by A11 antibody-covered SPR chip (CH1) and (B) fibrils of A β (1–42) by OC antibody-covered SPR chip (CH2). 10 μ M of A β (1–42) was incubated in 10 mM phosphate buffer (pH 7.4) at 37 $^{\circ}$ C for 0 h (a), 1 h (b), 2 h (c), 4 h (d), 6 h (e), 10 h (f) and 24 h (g).




Fig. 3 The influence of curcumin (B), Cu²⁺ (C) and methylene blue (D) on the oligomer formation. 10 μ M of A β (1–42) was incubated at 37 $^{\circ}$ C alone (A), with 10 μ M curcumin (B) or 20 μ M Cu²⁺ (C) or 300 μ M methylene blue (D) for 1, 2, 4, 6, 10 and 24 h. The above solutions were then flowed over the A11 antibody-covered sensor chip (CH1).

tion.⁴¹ When adding methylene blue into the A β (1–42) solution, we found that the oligomer formation was increased slowly and the maximum SPR signal was obtained after incubation for 24 h (Fig. 3D). Thus, methylene blue lowered the aggregation rate of A β (1–42) from monomers to oligomers or promoted the aggregation rate of oligomers to fibrils, which decreased the amount of toxic oligomers.

The influence of curcumin, Cu²⁺ and methylene blue on the fibril formation was also studied. Fig. 4 shows the time-dependent distribution of the fibrils in the absence (A) and presence of curcumin (B), Cu²⁺ (C) and methylene blue (D). A gradual increase in the SPR signals was observed upon injection of the A β (1–42) solution onto the fibril-specific OC antibody-covered SPR chip, and a maximum value was obtained after incubation for 24 h (Fig. 4A and 2B). In the presence of curcumin, the tendency for fibril formation was much lower (Fig. 4B), suggesting that curcumin inhibits the formation of fibrils. Such an inhibition effect may be ascribed to the formation of a lower amount of oligomers (Fig. 3B). In contrast, the presence of Cu²⁺ accelerated the fibril formation within 2 h, and beyond 2 h, the tendency began to level off (Fig. 4C). In comparison with that in the case of A β (1–42) alone, methylene blue promoted the fibril formation and a gradual increase in the SPR signals was attained (Fig. 4D).

Taken together, curcumin suppressed the formation of both oligomers and fibrils, while Cu²⁺ served as a promoter of A β aggregation within a shorter incubation time period (~2 h). For methylene blue, it promoted the aggregation of A β (1–42) oligomers to fibrils. The above results are in good agreement with those reported.^{36–39,42} For example, Cole and coworkers and Palumaa and coworkers demonstrated that curcumin was an oligomer-specific inhibitor and hindered the fibril for-

mation.^{36,37} Cu²⁺ could dramatically induce A β aggregation and treatment with a Cu²⁺ chelator markedly and rapidly inhibiting the process.^{38,39} Methylene blue was shown as a promoter of A β aggregation by Glabe and coworkers, which inhibited A β oligomerization by promoting the fibrillization process.⁴² Thus, the oligomerization and fibrillization pathways of A β (1–42) are distinct and methylene blue stabilizes the fibrillized conformation.⁴²

For clarity, we compared the SPR responses at the OC antibody-covered SPR chips (CH2) upon incubation of A β (1–42) in the absence and presence of curcumin or Cu²⁺ or methylene blue for 6 h (Fig. 5A). The highest SPR signal was obtained in the presence of methylene blue, again indicating that methylene blue is a promoter of the fibril formation. However, the presence of the inhibitor of curcumin results in a much smaller SPR signal. Cu²⁺ serves as a promoter of the fibril formation within 2 h (Fig. 4C), and similar SPR responses were observed in the absence and presence of Cu²⁺ upon incubation for 6 h (Fig. 5A). To further validate the above data, the ThT fluorescence assay was performed (Fig. 5B). ThT, which has been widely used for monitoring of A β aggregation, associates rapidly with the aggregated fibrils.³⁵ The comparative analysis indicates that the overall trend by the ThT assay matched closely with that by SPR at numerous time points, demonstrating the validity of the proposed method. It is worth noting that the accuracy for the SPR assay of both oligomers and fibrils on one single chip was significantly improved. Furthermore, excellent reproducibility and throughput could be achieved *via* chip regenerations. Therefore, SPR may serve as a reasonable means for monitoring the formation and distribution of the various A β aggregates.

Finally, the inhibition assay of curcumin (A) and methylene blue (B) on the oligomer formation was conducted (Fig. 6). The SPR signals were remarkably decreased at lower concentrations and then plateaued at the elevated ones. IC₅₀, the half maximal inhibitory concentration, was estimated to be 0.7 μ M for curcumin and 37 μ M for methylene blue. Kim *et al.* also reported that curcumin had a strong inhibitory effect on A β




Fig. 4 The influence of curcumin (B), Cu²⁺ (C) and methylene blue (D) on the fibril formation. 10 μ M of A β (1–42) was incubated at 37 °C alone (A), with 10 μ M curcumin (B) or 20 μ M Cu²⁺ (C) or 300 μ M methylene blue (D) for 1, 2, 4, 6, 10 and 24 h. The above solutions were then flowed over the OC antibody-covered sensor chip (CH2).




Fig. 5 (A) Comparison of the SPR sensorgrams showing the fibril formation in the absence and presence of curcumin or Cu²⁺ or methylene blue. 10 μ M of A β (1–42) was incubated at 37 °C alone, and with 10 μ M curcumin or 20 μ M Cu²⁺ or 300 μ M methylene blue for 6 h. The above solutions were then flowed over the OC antibody-modified SPR chip (CH2). (B) Time-dependent ThT fluorescence in the presence of 10 μ M A β (1–42), the mixture of 10 μ M A β (1–42) with 10 μ M curcumin or 20 μ M Cu²⁺ or 300 μ M methylene blue. The intensity values were normalized to A β incubated alone for 24 h.




Fig. 6 Dependence of the SPR responses on the concentrations of curcumin and methylene blue. 10 μM of A β (1–42) was mixed with various concentrations of curcumin (A) or methylene blue (B) for 6 h and the above solutions were flowed over the A11 antibody-modified SPR chips (CH1).

oligomer formation ($\text{IC}_{50} = 0.68 \mu\text{M}$) by performing the ThT assay.⁴³ Thus, SPR is capable of monitoring of A β aggregation and screening of select inhibitors.

Conclusions

A SPR biosensor for simultaneously monitoring the distribution of A β (1–42) oligomers and fibrils in one single assay has been developed. The employment of the A11 and OC antibodies, which recognize the conformations of the oligomers and fibrils, respectively, enables the multiplexed capability of the assay. The proposed method has been utilized for efficient screening of select inhibitors and promoters. The presence of curcumin remarkably disrupted the aggregation process of A β (1–42), resulting in a decrease in the amount of both oligomers and fibrils. In contrast, Cu^{2+} was found to increase the formation of both oligomers and fibrils within a shorter incubation time period (~ 2 h), while methylene blue promoted the fibrillization of A β by inhibiting the oligomerization process. Though only the oligomers and fibrils were determined, we envision that the multiplexed assay of various species, such as monomers, oligomers, protofibrils, and fibrils can be realized by multiple SPR channels. Thus, SPR serves as an effective means for monitoring A β aggregation profiles and high-throughput screening of inhibitors and promoters.

Acknowledgements

The authors thank the National Natural Science Foundation of China (no. 21175156, 21575166 and 21375150) and China Post-doctoral Science Foundation (no. 2015M580696) for support. We also thank Dr Feimeng Zhou at California State University, Los Angeles for his useful comments.

Notes and references

- 1 J. Hardy and D. J. Selkoe, *Science*, 2002, **297**, 353–356.
- 2 D. J. Selkoe, *Behav. Brain Res.*, 2008, **192**, 106–113.

- 3 C. Haass, M. G. Schlossmacher, A. Y. Hung, C. Vigopelfrey, A. Mellon, B. L. Ostaszewski, I. Lieberburg, E. H. Koo, D. Schenk, D. B. Teplow and D. J. Selkoe, *Nature*, 1992, **359**, 322–325.
- 4 D. M. Walsh, I. Klyubin, J. V. Fadeeva, W. K. Cullen, R. Anwyl, M. S. Wolfe, M. J. Rowan and D. J. Selkoe, *Nature*, 2002, **416**, 535–539.
- 5 Y. Gong, L. Chang, K. L. Viola, P. N. Lacor, M. P. Lambert, C. E. Finch, G. A. Krafft and W. L. Klein, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 10417–10422.
- 6 C. A. McLean, R. A. Cherny, F. W. Fraser, S. J. Fuller, M. J. Smith, K. Beyreuther, A. I. Bush and C. L. Masters, *Ann. Neurol.*, 1999, **46**, 860–866.
- 7 L. F. Lue, Y. M. Kuo, A. E. Roher, L. Brachova, Y. Shen, L. Sue, T. Beach, J. H. Kurth, R. E. Rydel and J. Rogers, *Am. J. Pathol.*, 1999, **155**, 853–862.
- 8 J. E. Ladbury, *Biochem. Soc. Trans.*, 2010, **38**, 888–893.
- 9 S. Sinha, J. P. Anderson, R. Barbour, G. S. Basi, R. Caccavello, D. Davis, M. Doan, H. F. Dovey, N. Frigon, J. Hong, K. Jacobson-Croak, N. Jewett, P. Keim, J. Knops, I. Lieberburg, M. Power, H. Tan, G. Tatsuno, J. Tung, D. Schenk, P. Seubert, S. M. Suomensaaari, S. W. Wang, D. Walker, J. Zhao, L. McConlogue and V. John, *Nature*, 1999, **402**, 537–540.
- 10 R. Vassar, *Adv. Drug Delivery Rev.*, 2002, **54**, 1589–1602.
- 11 K. Iwata, T. Fujiwara, Y. Matsuki, H. Akutsu, S. Takahashi, H. Naiki and Y. Goto, *Proc. Natl. Acad. Sci. U. S. A.*, 2006, **103**, 18119–18124.
- 12 I. A. Mastrangelo, M. Ahmed, T. Sato, W. Liu, C. P. Wang, P. Hough and S. O. Smith, *J. Mol. Biol.*, 2006, **358**, 106–119.
- 13 M. Sunde, L. C. Serpell, M. Bartlam, P. E. Fraser, M. B. Pepys and C. C. Blake, *J. Mol. Biol.*, 1997, **273**, 729–739.
- 14 L. P. Jameson, N. W. Smith and S. V. Dzyuba, *ACS Chem. Neurosci.*, 2012, **3**, 807–819.
- 15 M. Groenning, *J. Chem. Biol.*, 2010, **3**, 1–18.
- 16 F. Meng, P. Marek, K. J. Potter, C. B. Verchere and D. P. Raleigh, *Biochemistry*, 2008, **47**, 6016–6024.
- 17 B. Y. Feng, B. H. Toyama, H. Wille, D. W. Colby, S. R. Collins, B. C. H. May, S. B. Prusiner, J. Weissman and B. K. Shoichet, *Nat. Chem. Biol.*, 2008, **4**, 197–199.
- 18 H. Hillen, S. Barghorn, A. Striebing, B. Labkovsky, R. Muller, V. Nimmrich, M. W. Nolte, C. Perez-Cruz, I. van der Auwera, F. van Leuven, M. van Gaalen, A. Y. Bessalov, H. Schoemaker, J. P. Sullivan and U. Ebert, *J. Neurosci.*, 2010, **30**, 10369–10379.
- 19 A. C. Klaver, L. M. Patrias, M. P. Coffey, J. M. Finke and D. A. Loeffler, *J. Neurosci. Methods*, 2010, **187**, 263–269.
- 20 B. Alies, H. Eury, M. Essassi el, G. Pratviel, C. Hureau and P. Faller, *Anal. Chem.*, 2014, **86**, 11877–11882.
- 21 J. Lee, E. K. Culyba, E. T. Powers and J. W. Kelly, *Nat. Chem. Biol.*, 2011, **7**, 602–609.
- 22 S. D. Quinn, P. A. Dalgarno, R. T. Cameron, G. J. Hedley, C. Hacker, J. M. Lucocq, G. S. Baillie, I. D. W. Samuel and J. C. Penedo, *Mol. Biosyst.*, 2014, **10**, 34–44.

- 23 N. Xia, L. Liu, M. G. Harrington, J. Wang and F. Zhou, *Anal. Chem.*, 2010, **82**, 10151–10157.
- 24 X. Yi, Y. Hao, N. Xia, J. Wang, M. Quintero, D. Li and F. Zhou, *Anal. Chem.*, 2013, **85**, 3660–3666.
- 25 J. Homola, *Chem. Rev.*, 2008, **108**, 462–493.
- 26 M. J. Linman, A. Abbas and Q. A. Cheng, *Analyst*, 2010, **135**, 2759–2767.
- 27 S. Wang, S. Boussaad and N. J. Tao, *Rev. Sci. Instrum.*, 2001, **72**, 3055–3060.
- 28 J. Ryu, H.-A. Joung, M.-G. Kim and C. B. Park, *Anal. Chem.*, 2008, **80**, 2400–2407.
- 29 X. R. Cheng, B. Y. Hau, A. J. Veloso, S. Martic, H. B. Kraatz and K. Kerman, *Anal. Chem.*, 2013, **85**, 2049–2055.
- 30 G. D. VanWiggeren, M. A. Bynum, J. P. Ertel, S. Jefferson, K. A. Robotti, E. P. Thrush, D. A. Baney and K. P. Killeen, *Sens. Actuator, B*, 2007, **127**, 341–349.
- 31 A. J. Veloso, A. M. Chow, H. V. Ganesh, N. Li, D. Dhar, D. C. Wu, S. Mikhaylichenko, I. R. Brown and K. Kerman, *Anal. Chem.*, 2014, **86**, 4901–4909.
- 32 S. Lofas, *Pure Appl. Chem.*, 1995, **67**, 829–834.
- 33 R. Kaye, E. Head, J. L. Thompson, T. M. McIntire, S. C. Milton, C. W. Cotman and C. G. Glabe, *Science*, 2003, **300**, 486–489.
- 34 R. Kaye, E. Head, F. Sarsoza, T. Saing, C. W. Cotman, M. Necula, L. Margol, J. Wu, L. Breydo, J. L. Thompson, S. Rasool, T. Gurlo, P. Butler and C. G. Glabe, *Mol. Neurodegener.*, 2007, **2**, 18.
- 35 S. W. Snyder, U. S. Lador, W. S. Wade, G. T. Wang, L. W. Barrett, E. D. Matayoshi, H. J. Huffaker, G. A. Krafft and T. F. Holzman, *Biophys. J.*, 1994, **67**, 1216–1228.
- 36 F. Yang, G. P. Lim, A. N. Begum, O. J. Ubeda, M. R. Simmons, S. S. Ambegaokar, P. P. Chen, R. Kaye, C. G. Glabe, S. A. Frautschy and G. M. Cole, *J. Biol. Chem.*, 2005, **280**, 5892–5901.
- 37 K. Zovo, E. Helk, A. Karafin, V. Tougu and P. Palumaa, *Anal. Chem.*, 2010, **82**, 8558–8565.
- 38 C. S. Atwood, R. D. Moir, X. Huang, R. C. Scarpa, N. M. Bacarra, D. M. Romano, M. A. Hartshorn, R. E. Tanzi and A. I. Bush, *J. Biol. Chem.*, 1998, **273**, 12817–12826.
- 39 R. A. Cherny, C. S. Atwood, M. E. Xilinas, D. N. Gray, W. D. Jones, C. A. McLean, K. J. Barnham, I. Volitakis, F. W. Fraser, Y. S. Kim, X. D. Huang, L. E. Goldstein, R. D. Moir, J. T. Lim, K. Beyreuther, H. Zheng, R. E. Tanzi, C. L. Masters and A. I. Bush, *Neuron*, 2001, **30**, 665–676.
- 40 X. Huang, M. P. Cuajungco, C. S. Atwood, M. A. Hartshorn, J. D. A. Tyndall, G. R. Hanson, K. C. Stokes, M. Leopold, G. Multhaup, L. E. Goldstein, R. C. Scarpa, A. J. Saunders, J. Lim, R. D. Moir, C. Glabe, E. F. Bowden, C. L. Masters, D. P. Fairlie, R. E. Tanzi and A. I. Bush, *J. Biol. Chem.*, 1999, **274**, 37111–37116.
- 41 M. Oz, D. E. Lorke and G. A. Petroianu, *Biochem. Pharmacol.*, 2009, **78**, 927–932.
- 42 M. Necula, L. Breydo, S. Milton, R. Kaye, W. E. van der Veer, P. Tone and C. G. Glabe, *Biochemistry*, 2007, **46**, 8850–8860.
- 43 H. Kim, B. S. Park, K. G. Lee, C. Y. Choi, S. S. Jang, Y. H. Kim and S. E. Lee, *J. Agric. Food Chem.*, 2005, **53**, 8537–8541.